Enanta Pharmaceuticals entered into an Open Market Sale Agreement with Jefferies to sell up to $75 million of common stock through an at-the-market program. Shares may be sold from time to time on The Nasdaq Global Select Market, with Jefferies earning a commission of up to 3.0% of gross proceeds. The company is not obligated to sell any shares and can set price, timing, and size parameters. The program is effective under Enanta’s shelf registration and is intended to enhance financial flexibility.
Agreement details:
- Agreement type: Open Market Sale Agreement (at-the-market offering program)
- Counterparty: Jefferies
- Signed / Effective: Jul 02 2026 / Jul 02 2026
- Duration / Termination: At will
- Reason: Bolster liquidity and funding flexibility
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.